Squarepoint Ops LLC Raises Holdings in Solventum Corporation $SOLV

Squarepoint Ops LLC boosted its position in shares of Solventum Corporation (NYSE:SOLV) by 6,103.8% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 243,128 shares of the company’s stock after acquiring an additional 239,209 shares during the quarter. Squarepoint Ops LLC’s holdings in Solventum were worth $18,757,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. United Services Automobile Association acquired a new position in shares of Solventum in the first quarter valued at approximately $239,000. Woodline Partners LP grew its position in Solventum by 40.7% in the 1st quarter. Woodline Partners LP now owns 11,677 shares of the company’s stock valued at $888,000 after buying an additional 3,377 shares during the last quarter. Intech Investment Management LLC increased its stake in Solventum by 167.0% in the 1st quarter. Intech Investment Management LLC now owns 16,669 shares of the company’s stock valued at $1,268,000 after buying an additional 10,425 shares during the period. First Trust Advisors LP raised its position in Solventum by 5.8% during the 2nd quarter. First Trust Advisors LP now owns 257,727 shares of the company’s stock worth $19,546,000 after buying an additional 14,151 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in Solventum during the 2nd quarter worth $766,000.

Solventum Stock Performance

SOLV opened at $90.13 on Thursday. Solventum Corporation has a 1-year low of $62.38 and a 1-year high of $94.16. The stock has a market cap of $15.34 billion, a P/E ratio of 11.02, a P/E/G ratio of 1.41 and a beta of 0.61. The stock’s 50 day simple moving average is $84.77 and its 200 day simple moving average is $76.37. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.02 and a quick ratio of 0.74.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The business had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.15 billion. During the same quarter in the previous year, the company posted $1.69 EPS. The business’s revenue was up 2.2% on a year-over-year basis. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, equities analysts anticipate that Solventum Corporation will post 7.22 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on SOLV. Wall Street Zen cut shares of Solventum from a “buy” rating to a “hold” rating in a report on Saturday, August 22nd. Mizuho set a $113.00 price objective on Solventum in a report on Thursday, August 6th. UBS Group boosted their target price on Solventum from $95.00 to $101.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. BTIG Research increased their target price on Solventum from $91.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, BMO Capital Markets started coverage on Solventum in a report on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 price target for the company. Eight research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $91.64.

About Solventum

Solventum Corporation (NYSE:SOLV) is a global healthcare company that develops products and technologies intended to improve patient care, support healthcare professionals and increase the efficiency of healthcare delivery. The company serves hospitals, clinics, dental practices, laboratories, government agencies and other healthcare-related organizations.

Its offerings include medical and surgical products such as wound-care, skin-care, infection-prevention and surgical solutions; dental products and materials; and health information systems that support clinical documentation, coding, workflow and decision-making.